The deal expands a deal to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using ...
Blockbuster weight loss medications from Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) lead Evaluate Pharma’s list of ...
Novo Nordisk shares fell 30% in the fourth quarter on disappointing clinical trial data, concerns about its experimental ...
Novo Nordisk shares fell nearly 30% in the fourth quarter on disappointing clinical trial data, and other concerns. Bank of ...
Investing.com – Denmark stocks were lower after the close on Tuesday, as losses in the Personal & Household Goods, Healthcare and Industrials sectors led shares lower. At the... Investing.com ...
Novo Nordisk is graded B on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
The investment continues a Novo dealmaking spree to cement its leadership status in the cardiometabolic space, with ...
Novo Nordisk and Valo Health have expanded their 16-month-old collaboration into an up-to-$4.6 billion-plus artificial ...
Looking to expand its legacy in metabolic conditions, Novo Nordisk has inked a multiyear research pact with Variant Bio to better understand the genetics underlying disease across diverse populatio | ...
1d
Aspect Biosystems secures $115M Series B to advance bioprinted tissue therapeutics, accelerating development of functional ...
A UK biotechnology startup is entering the crowded obesity drug market, armed with $411 million and a promising ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback